triazoles has been researched along with Nail Fungus in 126 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (2.38) | 18.2507 |
| 2000's | 10 (7.94) | 29.6817 |
| 2010's | 89 (70.63) | 24.3611 |
| 2020's | 24 (19.05) | 2.80 |
| Authors | Studies |
|---|---|
| Murota, H; Nishimoto, K; Takenaka, M | 1 |
| Garoufalis, MG | 1 |
| Gupta, AK; Talukder, M | 1 |
| Masumoto, A; Matsuda, Y; Nakamura, S; Sugiura, K; Takagi, M; Tatsumi, Y | 1 |
| Fukushima, S; Higuchi, S; Hiruma, M; Kano, R; Kashiwada-Nakamura, K; Kubo, M; Matsumoto, T; Noguchi, H; Satoh, T; Yaguchi, T | 1 |
| Kawai, M | 1 |
| Lin, K; Lipner, SR | 1 |
| Koo, KT; Lee, BC; Na, J; Pangeni, R; Park, JW | 1 |
| Kuwano, Y; Sei, Y; Shimoyama, H | 1 |
| Ahmad Nasrollahi, S; Azizzadeh-Roodpishi, S; Dowlatiy, Y; Ehsani, AH; Fattahi, A; Firooz, A; Ghasemi, Z; Malakooti, S; Naeimifar, A; Samadi, A | 1 |
| Lipner, SR; Wang, Y | 1 |
| Hamedani, E; Harkless, L; Navarrete, R; Seun, J; Shofler, D; Thamby, R | 1 |
| Geizhals, S; Lipner, SR; Wu, AG | 1 |
| Gupta, AK; Piguet, V; Shear, NH; Venkataraman, M | 1 |
| Eichenfield, LF; Elewski, B; Guenin, E; Gupta, AK; Pillai, R; Rosen, T; Sugarman, JL; Vlahovic, TC | 1 |
| Eichenfield, LF; Elewski, B; Guenin, E; Gupta, AK; Pillai, R; Rosen, T; Stein Gold, L; Sugarman, JL; Vlahovic, TC | 1 |
| Geizhals, S; Lipner, SR | 1 |
| Cooper, EA; Gupta, AK | 1 |
| Kasuya, A; Sato, T; Suzuki, T; Yaguchi, T | 1 |
| Agrawal, V; Mishra, S; Patel, M; Patel, R; Thanki, K | 1 |
| Akbari, F; Deng, S; Houbraken, J; Najafzadeh, MJ; Naseri, A; Wang, X; Xu, X; Zhang, H; Zhao, R | 1 |
| Choi, YS; Ho, MJ; Jang, SW; Kang, MJ; Kim, EA; Kim, JS; Park, DW; Park, JS | 1 |
| Aoi, J; Fukushima, S; Kashiwada-Nakamura, K; Kubo, M; Makino, K; Noguchi, H | 1 |
| Gupta, AK; Vlahovic, TC | 1 |
| Abe, M; Fujii, M; Fukuzawa, M; Hattori, N; Iozumi, K; Ito, Y; Kasai, H; Kato, F; Kato, I; Kiryu, H; Kodama, K; Kusuhara, M; Maruyama, R; Mayama, J; Mochizuki, T; Muramoto, F; Nakasu, I; Nishimoto, S; Oh-I, T; Omi, T; Onoduka, T; Seishima, M; Shimoyama, H; Shindo, M; Sugiura, K; Takahashi, H; Takeda, O; Takenaka, M; Tateishi, Y; Tomizawa, K; Tsuboi, R; Uesugi, T; Watanabe, S; Watanabe-Okada, E; Yamamoto, O; Yamanaka, K; Yasuda, H | 1 |
| Anbalagan, N; Guenin, EP; Gupta, AK; Venkataraman, M | 1 |
| Abramovits, W; Guenin, EP; Gupta, AK; Venkataraman, M | 1 |
| Cook-Bolden, FE; Lin, T | 1 |
| Adigun, CG; Gellings Lowe, N; Hall, SB; Joseph, WS; Rich, P; Vlahovic, TC; Zane, LT | 1 |
| Hasuko, M; Hirano, H; Inagaki, K; Motoba, K; Shiomi, R; Takahashi, Y; Tsuboi, R | 1 |
| Ilie, C; Pollak, RA | 1 |
| Cantrell, W; Elewski, BE; Lin, T | 1 |
| Imazu, Y; Suzuki, J; Uchida, E; Yamaura, K; Yoneta, Y | 1 |
| Hayashi, N; Imazu, Y; Suzuki, J; Uchida, E; Yamaura, K; Yoneta, Y | 1 |
| Ishii, Y; Ito, Y; Matsuki, S; Ogawa, O; Sanpei, K; Schuck, EL; Takeda, K; Uemura, N | 1 |
| Lipner, SR; Scher, RK | 3 |
| Baltazar, LM; Costa-Orlandi, CB; Friedman, AJ; Friedman, JM; Mendes-Giannini, MJS; Mordorski, B; Nosanchuk, JD | 1 |
| Asao, K; Fukushima, S; Hirose, M; Hiruma, M; Ihn, H; Matsumoto, T; Noguchi, H | 1 |
| Bonhert, K; Dorizas, A; Sadick, NS | 1 |
| Fukushima, S; Hirose, M; Hiruma, M; Ihn, H; Matsumoto, T; Noguchi, H; Yaguchi, T | 1 |
| Okubo, A; Tsubouchi, I; Watanabe, S | 1 |
| Hur, MS; Jung, WH; Lee, YW; Park, M | 1 |
| Ko, D; Lipner, SR | 1 |
| Abe, M; Fujii, M; Fukuzawa, M; Hata, Y; Hattori, N; Iozumi, K; Ito, Y; Kasai, H; Katayama, I; Kato, F; Kato, I; Kiryu, H; Kodama, K; Kusuhara, M; Maruyama, R; Mayama, J; Mochizuki, T; Muramoto, F; Nakasu, I; Nishimoto, S; Nomiyama, T; Oh-I, T; Omi, T; Onoduka, T; Sato, T; Sei, Y; Seishima, M; Shimoyama, H; Shindo, M; Sugiura, K; Takahashi, H; Takeda, O; Takenaka, M; Tomizawa, K; Tsuboi, R; Uesugi, T; Watanabe, S; Yamamoto, O; Yamanaka, K; Yasuda, H | 1 |
| Fukushima, S; Hiruma, M; Ihn, H; Kano, R; Kimura, U; Matsumoto, T; Noguchi, H; Yaguchi, T | 2 |
| Fata, A; Najafzadeh, MJ; Naseri, A | 1 |
| Malahias, S; Raterink, K; Sigurgeirsson, B; van Rossem, K | 1 |
| Rich, P | 2 |
| Jarratt, M; Kodera, N; Pillai, R; Siu, WJ; Smith, K; Yamakawa, E | 1 |
| Chen, H; Chen, M; Liao, W; Pan, W; Zhou, J | 1 |
| Tosti, A | 1 |
| Dhillon, S; Patel, T | 1 |
| Lipner, S; Scher, RK | 1 |
| Jim, SC; Kircik, LH; Routt, ET; Zeichner, JA | 1 |
| Arakawa, Y; Hosaka, S; Jo Siu, W; Katafuchi-Nagashima, M; Pillai, R; Sugimoto, N; Sugiura, K; Tatsumi, Y | 1 |
| Gupta, AK; Simpson, FC | 1 |
| Iwata, A; Katafuchi-Nagashima, M; Kumagai, N; Pillai, R; Sugiura, K; Tatsumi, Y; Watanabe, Y | 1 |
| Elewski, BE; Gupta, AK; Ieda, C; Kang, R; Kawabata, H; Olin, JT; Pillai, R; Sugarman, JL; Watanabe, S | 1 |
| Calvarese, B; Glynn, M; Jo, W; Minowa, K; Mutter, L; Nejishima, H; Pillai, R; Sanada, H; Senda, H | 1 |
| Pollak, RA | 1 |
| Al-Hatmi, AM; Bonifaz, A; Calderón, L; Curfs-Breuker, I; de Hoog, GS; Meis, JF; van Diepeningen, AD | 1 |
| Joseph, WS; Vlahovic, TC | 1 |
| Kawabata, H; Kodera, N; Pillai, R; Sakamoto, M; Sugimoto, N; Tatsumi, Y; Yamakawa, E | 1 |
| Elewski, BE; Olin, JT; Pillai, R; Pollak, RA | 1 |
| Kircik, LH | 1 |
| Bhatia, N; Friedlander, SF; Gupta, AK; Kircik, L; Rosen, T; Stein Gold, L; Zirwas, MJ | 1 |
| Bhatt, V; Pillai, R | 1 |
| Canavan, T; Cantrell, W; Elewski, B | 1 |
| Tatsumi, Y | 1 |
| Hanafusa, T; Hirohata, A; Ikegami, R; Mabuchi-Kiyohara, E | 1 |
| Bhatia, N | 1 |
| Feng, X; Liao, W; Ling, B; Pan, W; Yang, X; Yao, Z | 1 |
| Gupta, AK; Pillai, R | 1 |
| Jellinek, NJ; Korotzer, A | 1 |
| Caldwell, B; Markinson, B | 1 |
| Rosen, T | 2 |
| Cohen, J; Joyce, C; Mikailov, A; Mostaghimi, A | 1 |
| Kanzler, MH | 1 |
| Chanda, S; Coronado, D; Merchant, T; Vlahovic, TC; Zane, LT | 1 |
| Cernea, M; Gupta, AK | 1 |
| Dorval, E; Grace, Y; Machin, JD; Poulakos, M | 1 |
| Hossin, B; Murdan, S; Rizi, K | 1 |
| Bhatia, N; Caldwell, B; Elewski, BE; Gupta, AK; Kircik, LH; Pariser, DM; Rosen, T; Tosti, A | 1 |
| Rosen, T; Stein Gold, LF | 3 |
| Chanda, S; Coronado, D; Del Rosso, J; Zane, LT | 1 |
| Lagrew, JP | 1 |
| Elewski, BE | 1 |
| Hiruma, M; Ihn, H; Kano, R; Matsumoto, T; Noguchi, H | 2 |
| Akiti, T; Barreiros, G; Nouér, SA; Nucci, M; Trope, BM; Varon, AG | 1 |
| Gupta, AK; Korotzer, A | 1 |
| Gupta, AK; Studholme, C | 1 |
| Yamaguchi, H | 1 |
| Hirayanagi, K; Imai, A; Iwanaga, T; Kubota, N; Miyamae, A; Shibuya, K; Shimamura, T | 1 |
| Furuya, K; Hoshina, D; Yamaguchi, Y | 1 |
| Kawada, A; Oiso, N; Tatebayashi, M | 1 |
| Alastruey-Izquierdo, A; Araujo Ribeiro, M; Cuenca-Estrella, M; Gomez-Lopez, A; Rodriguez-Tudela, JL | 1 |
| Kimball, AB; Kumar, S | 1 |
| Bueno, JG; Gallego, M; Martinez, C; Mesa, AC; Sanclemente, G; Zapata, B | 1 |
| Beresford, E; Komjathy, S; Krishna, G; Ma, L; Martinho, M; Tavakkol, A; Vickery, D; Yu, X | 1 |
| Vera-Cabrera, L; Welsh, E; Welsh, O | 1 |
| Hall, AJ; Kam, JK; Morrissey, O; Szental, JA; Yohendran, J | 1 |
| Krishna, G; Ma, L; Martinho, M; Prasad, P; Tavakkol, A; Wahl, J | 1 |
| Ashton, S; Elewski, B; Pollak, R; Rich, P; Schlessinger, J; Tavakkol, A | 1 |
| Elewski, BE; Ieda, C; Olin, JT; Pariser, DM; Pillai, R; Pollak, R; Ramakrishna, T; Rich, P; Senda, H; Smith, K; Watanabe, S | 1 |
| Fothergill, A; Jo Siu, WJ; Nakamura, T; Pillai, R; Senda, H; Sone, D; Tatsumi, Y | 1 |
| Bucko, AD; Kawabata, H; Oizumi, N; Olin, JT; Pillai, R; Tschen, EH | 1 |
| Kakehi, K; Senda, H; Tatsumi, Y; Yokoo, M | 1 |
| Conetta, B; Gupta, AK; Leonardi, C; Pierce, PF; Stoltz, RR | 1 |
| Selleslag, D | 1 |
| Borrego, L; Hernández, J; Hernández-Machín, B; Islas, D; Martín, AM; Peñate, Y | 1 |
| Loo, DS | 1 |
| Sellart-Altisent, M; Torres-Rodríguez, JM | 1 |
| Cárdenes, CD; Carrillo-Muñoz, AJ; del Valle, O; Estivill, D; Giusiano, G; Guardia, C; Guarro, J; Quindós, G; Rodríguez, V | 1 |
| Dunand, J; Paugam, A | 1 |
| Chiritescu, ME; Chiritescu, MM; Scher, RK | 1 |
| Alchorne, MM; Fischman, O; Kaminski, SK; Palmeira, Mdo C; Porro, AM; Yoshioka, MC | 1 |
| Hernanz Hermosa, JM; Lázaro Ochaita, P | 1 |
24 review(s) available for triazoles and Nail Fungus
| Article | Year |
|---|---|
Efinaconazole in Onychomycosis.
Topics: Administration, Topical; Adult; Antifungal Agents; Child; Female; Humans; Onychomycosis; Triazoles | 2022 |
Characteristics and Efficacy of Two Topical Therapeutic Agents for Onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Drug Resistance, Fungal; Humans; Imidazoles; Keratins; Nails; Onychomycosis; Solutions; Triazoles; Trichophyton | 2019 |
A Timeline of Onychomycosis Therapy and Future Directions.
Topics: Administration, Topical; Antifungal Agents; Humans; Itraconazole; Nail Diseases; Onychomycosis; Terbinafine; Triazoles | 2020 |
Efinaconazole topical solution (10%) for the treatment of onychomycosis in adult and pediatric patients.
Topics: Administration, Topical; Adult; Antifungal Agents; Child; Humans; Onychomycosis; Pediatrics; Triazoles | 2022 |
One size does not fit all: the need for individualized treatment based on factors that may affect the therapeutic outcome of efinaconazole 10% solution for the treatment of toenail onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Foot Dermatoses; Humans; Nails; Onychomycosis; Quality of Life; Treatment Outcome; Triazoles | 2021 |
Onychomycosis: Treatment and prevention of recurrence.
Topics: Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Fluconazole; Humans; Itraconazole; Laser Therapy; Nanoparticles; Onychomycosis; Photochemotherapy; Plasma Gases; Prognosis; Pulse Therapy, Drug; Risk Factors; Secondary Prevention; Severity of Illness Index; Terbinafine; Triazoles | 2019 |
Rhodotorula minuta as onychomycosis agent in a Chinese patient: first report and literature review.
Topics: Adolescent; Amphotericin B; Antifungal Agents; Asian People; China; Drug Resistance, Fungal; Female; Fluconazole; Humans; Itraconazole; Microbial Sensitivity Tests; Onychomycosis; Pyrimidines; Rhodotorula; Triazoles; Voriconazole | 2014 |
What is new in fungal pharmacotherapeutics?
Topics: Allylamine; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Education, Medical, Continuing; Humans; Imidazoles; Itraconazole; Onychomycosis; Tinea Pedis; Triazoles | 2014 |
The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: a pooled analysis of two phase 3 randomized trials.
Topics: Administration, Topical; Aged; Antifungal Agents; Clinical Trials, Phase III as Topic; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Pharmaceutical Solutions; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome; Triazoles | 2014 |
Efinaconazole topical solution, 10%: the development of a new topical treatment for toenail onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Foot Dermatoses; Humans; Onychomycosis; Triazoles | 2014 |
Enhancing transungual delivery and spreading of efinaconazole under the nail plate through a unique formulation approach.
Topics: Administration, Topical; Antifungal Agents; Chemistry, Pharmaceutical; Drug Delivery Systems; Humans; Nails; Onychomycosis; Permeability; Triazoles | 2014 |
Onychomycosis: epidemiology, diagnosis, and treatment in a changing landscape.
Topics: Anti-Infective Agents, Local; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Humans; Onychomycosis; Pharmaceutical Solutions; Treatment Outcome; Triazoles | 2015 |
[Pharmacological characteristics and clinical results of efinaconazole (Clenafin® Topical Solution 10%), a novel anti-onychomycosis drug].
Topics: Animals; Antifungal Agents; Clinical Trials as Topic; Drug Resistance; Humans; Onychomycosis; Pharmaceutical Solutions; Triazoles | 2015 |
Efinaconazole 10% topical solution for the topical treatment of onychomycosis of the toenail.
Topics: Administration, Topical; Animals; Antifungal Agents; Foot Dermatoses; Humans; Onychomycosis; Triazoles | 2015 |
Evaluation of gender as a clinically relevant outcome variable in the treatment of onychomycosis with efinaconazole topical solution 10.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Prospective Studies; Randomized Controlled Trials as Topic; Sex Factors; Treatment Outcome; Triazoles; Young Adult | 2015 |
Efinaconazole and Tavaborole.
Topics: Administration, Topical; Animals; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Foot Dermatoses; Humans; Microbial Sensitivity Tests; Onychomycosis; Triazoles | 2017 |
Antifungal agents for onychomycosis: new treatment strategies to improve safety.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Chemical and Drug Induced Liver Injury; Ciclopirox; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Itraconazole; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Triazoles | 2016 |
Ungual hyalohyphomycosis caused by Fusarium proliferatum in an immunocompetent patient.
Topics: Administration, Topical; Aged; Antifungal Agents; Female; Foot Dermatoses; Fusariosis; Fusarium; Humans; Hyphae; Naphthalenes; Onychomycosis; Terbinafine; Triazoles | 2017 |
Potential of Ravuconazole and its Prodrugs as the New OralTherapeutics for Onychomycosis.
Topics: Administration, Oral; Antifungal Agents; Arthrodermataceae; Candida; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Discovery; Humans; Onychomycosis; Prodrugs; Thiazoles; Triazoles | 2016 |
New antifungal therapies for the treatment of onychomycosis.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Drugs, Investigational; Foot Dermatoses; Hand Dermatoses; Humans; Microwaves; Onychomycosis; Photochemotherapy; Triazoles | 2009 |
Onychomycosis.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Ciclopirox; Drug Administration Schedule; Drug Therapy, Combination; Fluconazole; Foot Dermatoses; Humans; Itraconazole; Mitosporic Fungi; Morpholines; Naphthalenes; Onychomycosis; Pyridones; Pyrimidines; Terbinafine; Thiazoles; Triazoles; Voriconazole | 2010 |
Systemic antifungal agents: an update of established and new therapies.
Topics: Antifungal Agents; Humans; Onychomycosis; Tinea Capitis; Triazoles | 2006 |
Newer systemic antifungal drugs for the treatment of onychomycosis.
Topics: Aged; Antifungal Agents; Child; Enzyme Inhibitors; Female; Griseofulvin; HIV Infections; Humans; Imidazoles; Male; Naphthalenes; Onychomycosis; Terbinafine; Triazoles | 1996 |
[Superficial mycoses in immunosuppressed patients].
Topics: Adult; Antifungal Agents; Candidiasis, Cutaneous; Candidiasis, Oral; Candidiasis, Vulvovaginal; Child; Dermatitis, Seborrheic; Dermatomycoses; Female; Fluconazole; Humans; Imidazoles; Immunosuppression Therapy; Itraconazole; Ketoconazole; Male; Morpholines; Onychomycosis; Tinea; Tinea Versicolor; Transplantation; Triazoles | 1995 |
31 trial(s) available for triazoles and Nail Fungus
| Article | Year |
|---|---|
Efinaconazole topical solution 10%: Formulation and efficacy assessment in the treatment of toenail onychomycosis.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antifungal Agents; Female; Foot; Humans; Male; Middle Aged; Nail Diseases; Nails; Onychomycosis; Pilot Projects; Triazoles; Young Adult | 2020 |
Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients.
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Blood Glucose; Diabetes Complications; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Treatment Outcome; Triazoles | 2020 |
Labeled use of efinaconazole topical solution 10% in treating onychomycosis in children and a review of the management of pediatric onychomycosis.
Topics: Administration, Topical; Adolescent; Antifungal Agents; Child; Foot Dermatoses; Humans; Multicenter Studies as Topic; Onychomycosis; Triazoles | 2020 |
Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients: Open-label phase 4 study.
Topics: Administration, Cutaneous; Adolescent; Antifungal Agents; Child; Female; Foot Dermatoses; Humans; Male; Onychomycosis; Solutions; Treatment Outcome; Triazoles | 2021 |
Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Pediatric Patients.
Topics: Administration, Topical; Adolescent; Antifungal Agents; Area Under Curve; Child; Female; Follow-Up Studies; Foot Dermatoses; Fungi; Humans; Male; Onychomycosis; Severity of Illness Index; Solutions; Treatment Outcome; Triazoles | 2020 |
Long-term Efficacy and Safety of Once-daily Efinaconazole 10% Topical Solution (Jublia) for Dermatophyte Toenail Onychomycosis: An Interim Analysis.
Topics: Administration, Cutaneous; Aged; Antifungal Agents; Drug Administration Schedule; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Treatment Outcome; Triazoles | 2021 |
Long-Term Follow-up of Onychomycosis Patients Treated With Efinaconazole
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Onychomycosis; Treatment Outcome; Triazoles; Young Adult | 2017 |
Is Severity of Disease a Prognostic Factor for Cure Following Treatment of Onychomycosis?
Topics: Administration, Topical; Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Prognosis; Severity of Illness Index; Treatment Outcome; Triazoles; Young Adult | 2018 |
Clinical Drug-Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects.
Topics: Administration, Oral; Adult; Antifungal Agents; Biological Assay; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Metabolome; Onychomycosis; Prodrugs; Thiazoles; Triazoles; Young Adult | 2018 |
Efficacy of combination therapy with efinaconazole 10% solution and 1064 nm Nd:YAG laser for treatment of toenail onychomycosis.
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Combined Modality Therapy; Female; Follow-Up Studies; Foot Dermatoses; Humans; Laser Therapy; Lasers, Solid-State; Male; Middle Aged; Onychomycosis; Patient Satisfaction; Photography; Statistics, Nonparametric; Treatment Outcome; Triazoles | 2019 |
Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study.
Topics: Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Prodrugs; Thiazoles; Treatment Outcome; Triazoles; Young Adult | 2018 |
Efficacy of long-term treatment with efinaconazole 10% solution in patients with onychomycosis, including severe cases: A multicenter, single-arm study.
Topics: Administration, Topical; Aged; Antifungal Agents; Drug-Related Side Effects and Adverse Reactions; Female; Foot Dermatoses; Humans; Incidence; Long-Term Care; Male; Middle Aged; Onychomycosis; Quality of Life; Severity of Illness Index; Time Factors; Treatment Outcome; Triazoles | 2019 |
A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis.
Topics: Administration, Oral; Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Quinazolines; Time Factors; Treatment Outcome; Triazoles; Young Adult | 2013 |
Safety and pharmacokinetics of efinaconazole 10% solution in healthy volunteers and patients with severe onychomycosis.
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Area Under Curve; Dose-Response Relationship, Drug; Drug Interactions; Ethnicity; Female; Half-Life; Humans; Male; Middle Aged; Nails; Onychomycosis; Pharmaceutical Solutions; Triazoles; Young Adult | 2013 |
Efinaconazole topical, 10% for the treatment of toenail onychomycosis in patients with diabetes.
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Diabetes Mellitus; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Treatment Outcome; Triazoles | 2014 |
Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails.
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Drug Delivery Systems; Female; Follow-Up Studies; Foot Dermatoses; Humans; In Vitro Techniques; Male; Microbial Sensitivity Tests; Middle Aged; Nails; Onychomycosis; Permeability; Triazoles; Trichophyton | 2014 |
Access of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual space.
Topics: Administration, Topical; Antifungal Agents; Female; Foot Dermatoses; Humans; Male; Middle Aged; Nails; Onychomycosis; Permeability; Treatment Outcome; Triazoles | 2014 |
Efinaconazole topical solution, 10%: the benefits of treating onychomycosis early.
Topics: Administration, Topical; Adult; Antifungal Agents; Disease Progression; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Prospective Studies; Time Factors; Treatment Outcome; Triazoles | 2015 |
Managing Assessments and Expectations: Patient Responses Following Therapy With Efinaconazole Topical Solution, 10%.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Nails; Onychomycosis; Patient Satisfaction; Severity of Illness Index; Treatment Outcome; Triazoles; Young Adult | 2015 |
The Presence of an Air Gap Between the Nail Plate and Nail Bed in Onychomycosis Patients: Treatment Implications for Topical Therapy.
Topics: Administration, Cutaneous; Adult; Aged; Air; Antifungal Agents; Female; Fluorescein; Foot Dermatoses; Humans; Male; Middle Aged; Nails; Onychomycosis; Pharmaceutical Vehicles; Severity of Illness Index; Triazoles | 2015 |
Prognostic Factors for Complete Cure Following Treatment of Mild and Moderate Toenail Onychomycosis With Efinaconazole Topical Solution 10.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Prognosis; Severity of Illness Index; Treatment Outcome; Triazoles; Young Adult | 2015 |
Efinaconazole Topical Solution, 10% Efficacy in Patients with Onychomycosis and Coexisting Tinea Pedis.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Onychomycosis; Tinea Pedis; Treatment Outcome; Triazoles; Young Adult | 2015 |
Cost-effectiveness of Confirmatory Testing Before Treatment of Onychomycosis.
Topics: Administration, Oral; Administration, Topical; Algorithms; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Decision Trees; Health Care Costs; Humans; Hydroxides; Naphthalenes; Onychomycosis; Periodic Acid-Schiff Reaction; Potassium Compounds; Potentially Inappropriate Medication List; Terbinafine; Triazoles | 2016 |
A financial perspective on the topical treatment of onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Costs; Female; Follow-Up Studies; Foot Dermatoses; Humans; Male; Onychomycosis; Risk Assessment; Treatment Outcome; Triazoles | 2016 |
Topical Treatment of Onychomycosis and Clinically Meaningful Outcomes.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Follow-Up Studies; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Treatment Outcome; Triazoles; Young Adult | 2016 |
Skin concentrations and pharmacokinetics of posaconazole after oral administration.
Topics: Administration, Oral; Adult; Antifungal Agents; Biopsy; Dermatomycoses; Female; Humans; Male; Middle Aged; Onychomycosis; Reference Values; Skin; Triazoles | 2010 |
Determination of posaconazole levels in toenails of adults with onychomycosis following oral treatment with four regimens of posaconazole for 12 or 24 weeks.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nails; Onychomycosis; Treatment Outcome; Triazoles; Young Adult | 2011 |
A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Drug Administration Schedule; Female; Foot Dermatoses; Humans; Male; Middle Aged; Naphthalenes; Onychomycosis; Tablets; Terbinafine; Treatment Outcome; Triazoles; Young Adult | 2012 |
Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Triazoles; Young Adult | 2013 |
Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind study.
Topics: Administration, Topical; Adult; Antifungal Agents; Chemistry, Pharmaceutical; Double-Blind Method; Female; Humans; Male; Middle Aged; Nails; Onychomycosis; Pharmaceutical Solutions; Research Design; Treatment Outcome; Triazoles; Young Adult | 2013 |
A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis.
Topics: Administration, Oral; Antifungal Agents; Double-Blind Method; Drug Administration Schedule; Foot Dermatoses; France; Humans; Nails; Ontario; Onychomycosis; Severity of Illness Index; Thiazoles; Treatment Outcome; Triazoles; United States | 2005 |
71 other study(ies) available for triazoles and Nail Fungus
| Article | Year |
|---|---|
Chronological evaluation of treatment effect for tinea unguium with efinaconazole: Possibility of an early estimation of treatment effects.
Topics: Administration, Topical; Antifungal Agents; Humans; Onychomycosis; Triazoles | 2021 |
Total Dystrophic Onychomycosis Successfully Treated with Efinaconazole Topical Solution in Times of Coronavirus Disease of 2019: A Case Study.
Topics: Administration, Topical; Adult; Antifungal Agents; Coronavirus; Female; Foot Dermatoses; Humans; Onychomycosis; Treatment Outcome; Triazoles | 2022 |
A novel method for predicting the efficacy of topical drugs on onychomycosis: A comparison of efinaconazole and luliconazole.
Topics: Administration, Topical; Antifungal Agents; Humans; Imidazoles; Nails; Onychomycosis; Triazoles | 2022 |
Onychomycosis Caused by Talaromyces muroii Successfully Treated with Efinaconazole.
Topics: Administration, Topical; Antifungal Agents; Foot Dermatoses; Humans; Onychomycosis; Talaromyces; Triazoles | 2023 |
Modeling of usage and estimation of cost for efinaconazole 10% topical solution in the treatment of onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Drug Costs; Foot Dermatoses; Healthy Volunteers; Humans; Nails; Onychomycosis; Solutions; Triazoles; United States | 2020 |
Preparation and
Topics: Administration, Topical; Animals; Antifungal Agents; Disease Models, Animal; Guinea Pigs; Humans; In Vitro Techniques; Male; Membranes, Artificial; Nails; Onychomycosis; Permeability; Skin; Skin Absorption; Tinea; Triazoles; Trichophyton | 2019 |
Retrospective Survey of Treatment Outcomes of Efinaconazole 10% Solution and Luliconazole 5% Solution for Onychomycosis in Our Facility.
Topics: Administration, Topical; Adult; Aged; Female; Humans; Imidazoles; Male; Middle Aged; Onychomycosis; Retrospective Studies; Solutions; Treatment Outcome; Triazoles | 2019 |
Retrospective analysis of adverse events with topical onychomycosis medications reported to the United States Food and Drug Administration.
Topics: Administration, Topical; Adverse Drug Reaction Reporting Systems; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Erythema; Humans; Nails; Onychomycosis; Pigmentation; Retrospective Studies; Solutions; Treatment Failure; Triazoles; United States; United States Food and Drug Administration | 2020 |
Retrospective study of factors affecting medication adherence in patients prescribed efinaconazole 10% solution for onychomycosis.
Topics: Administration, Topical; Age Factors; Antifungal Agents; Drug Prescriptions; Humans; Medication Adherence; Onychomycosis; Prescription Fees; Retrospective Studies; Triazoles | 2021 |
A Case of Tinea Faciei, Tinea Corporis, and Tinea Unguium with Dermatophytoma Successfully Treated with Oral Fosravuconazole L-lysine Ethanolate.
Topics: Administration, Oral; Aged; Arthrodermataceae; Humans; Male; Onychomycosis; Tinea; Treatment Outcome; Triazoles | 2021 |
Design and evaluation of microemulsion-based efinaconazole formulations for targeted treatment of onychomycosis through transungual route: Ex vivo and nail clipping studies.
Topics: Antifungal Agents; Arthrodermataceae; Emulsions; Humans; Nails; Onychomycosis; Triazoles | 2021 |
Identification and in vitro antifungal susceptibility of causative agents of onychomycosis due to Aspergillus species in Mashhad, Iran.
Topics: Antifungal Agents; Aspergillus; Calmodulin; Fungal Proteins; Humans; Iran; Microbial Sensitivity Tests; Nitriles; Onychomycosis; Pyridines; Sequence Analysis, DNA; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Triazoles; Tubulin; Voriconazole | 2021 |
Effect of Penetration Enhancers on Toenail Delivery of Efinaconazole from Hydroalcoholic Preparations.
Topics: Administration, Topical; Animals; Antifungal Agents; Cattle; Diffusion; Drug Carriers; Drug Delivery Systems; Hoof and Claw; Onychomycosis; Permeability; Propylene Glycol; Triazoles | 2021 |
Topical efinaconazole: A sequential combination therapy with oral terbinafine for refractory tinea unguium.
Topics: Administration, Topical; Antifungal Agents; Humans; Onychomycosis; Terbinafine; Triazoles | 2021 |
Clinical effectiveness of efinaconazole 10% solution for treatment of onychomycosis with longitudinal spikes.
Topics: Administration, Topical; Antifungal Agents; Humans; Onychomycosis; Treatment Outcome; Triazoles | 2021 |
JUBLIA (Efinaconazole 10% Solution) in the Treatment of Pediatric Onychomycosis.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antifungal Agents; Child; Foot Dermatoses; Humans; Onychomycosis; Terbinafine; Triazoles | 2021 |
Efinaconazole solution 10% for treatment of toenail onychomycosis in Latino patients.
Topics: Administration, Topical; Antifungal Agents; Female; Foot Dermatoses; Hispanic or Latino; Humans; Male; Middle Aged; Onychomycosis; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles; United States | 2017 |
Clinical trial designs for topical antifungal treatments of onychomycosis and implications on clinical practice.
Topics: Administration, Cutaneous; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Clinical Trials, Phase III as Topic; Drug Approval; Humans; Onychomycosis; Pyridones; Research Design; Treatment Outcome; Triazoles; United States | 2017 |
[Affinity of Luliconazole for Human Nail Derived Keratin].
Topics: Humans; Imidazoles; Keratins; Nails; Onychomycosis; Triazoles | 2017 |
[Current Status of Onychomycosis Topical Therapy Conducted at Home].
Topics: Antifungal Agents; Caregivers; Home Care Services; Humans; Infectious Disease Transmission, Professional-to-Patient; Onychomycosis; Triazoles | 2018 |
[Role of Pharmacists in Topical Therapy for Onychomycosis in the Home-care Setting].
Topics: Administration, Topical; Antifungal Agents; Community Pharmacy Services; Home Care Services; Humans; Japan; Onychomycosis; Patient Compliance; Pharmacists; Prevalence; Professional Role; Quality of Life; Triazoles | 2018 |
Nitric Oxide Releasing Nanoparticles as a Strategy to Improve Current Onychomycosis Treatments.
Topics: Administration, Topical; Animals; Antifungal Agents; Disease Models, Animal; Drug Carriers; Drug Liberation; Drug Synergism; Drug Therapy, Combination; Humans; Mice; Microbial Sensitivity Tests; Nanoparticles; Naphthalenes; Nitric Oxide; Onychomycosis; Permeability; Prescription Fees; Terbinafine; Treatment Outcome; Triazoles; Trichophyton | 2018 |
Topical efinaconazole: A promising therapeutic medication for tinea unguium.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifungal Agents; Female; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Photography; Treatment Outcome; Triazoles | 2018 |
Onychomycosis caused by Aspergillus subramanianii.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Antifungal Agents; Aspergillosis; Aspergillus; Female; Foot Dermatoses; Humans; Hyphae; Japan; Microscopy; Onychomycosis; Terbinafine; Triazoles; Young Adult | 2018 |
Evaluation of drug susceptibility test for Efinaconazole compared with conventional antifungal agents.
Topics: Antifungal Agents; Candida albicans; Humans; Microbial Sensitivity Tests; Onychomycosis; Tinea; Triazoles; Trichophyton | 2019 |
Optimizing topical therapy for onychomycosis: the importance of patient education.
Topics: Administration, Topical; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Humans; Medication Adherence; Onychomycosis; Patient Education as Topic; Triazoles | 2018 |
Fungal melanonychia caused by Candida parapsilosis successfully treated with oral fosravuconazole.
Topics: Administration, Oral; Aged; Antifungal Agents; Candida parapsilosis; Female; Hand Dermatoses; Humans; Melanosis; Onychomycosis; Prodrugs; Thiazoles; Treatment Outcome; Triazoles | 2019 |
Tinea unguium caused by terbinafine-resistant Trichophyton rubrum successfully treated with fosravuconazole.
Topics: Aged; Antifungal Agents; Drug Resistance, Fungal; Female; Hand Dermatoses; Humans; Onychomycosis; Terbinafine; Thiazoles; Tinea; Triazoles | 2019 |
First case of Tritirachium oryzae as agent of onychomycosis and its susceptibility to antifungal drugs.
Topics: Adult; Antifungal Agents; Basidiomycota; DNA, Fungal; DNA, Ribosomal Spacer; Female; Humans; Iran; Itraconazole; Microbial Sensitivity Tests; Microbiological Techniques; Microscopy; Molecular Sequence Data; Nails; Onychomycosis; Sequence Analysis, DNA; Triazoles | 2013 |
Topical treatment of onychomycosis with efinaconazole solution 10%.
Topics: Adult; Antifungal Agents; Foot Dermatoses; Humans; Male; Onychomycosis; Triazoles; Trichophyton | 2013 |
Efinaconazole solution 10%: topical antifungal therapy for toenail onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Foot Dermatoses; Humans; Onychomycosis; Recurrence; Triazoles | 2013 |
Efinaconazole: first global approval.
Topics: Administration, Topical; Animals; Antifungal Agents; Drug Approval; Humans; Onychomycosis; Pharmaceutical Solutions; Triazoles | 2013 |
Onychomycosis: current and future therapies.
Topics: Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Debridement; Foot Dermatoses; Hand Dermatoses; Humans; Laser Therapy; Morpholines; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Triazoles | 2014 |
The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.
Topics: Administration, Topical; Animals; Antifungal Agents; Guinea Pigs; Humans; In Vitro Techniques; Keratins; Microbial Sensitivity Tests; Nails; Onychomycosis; Tinea; Triazoles; Trichophyton | 2014 |
Efinaconazole (Jublia) for the treatment of onychomycosis.
Topics: 14-alpha Demethylase Inhibitors; Administration, Topical; Clinical Trials as Topic; Ergosterol; Humans; Microbial Sensitivity Tests; Onychomycosis; Triazoles | 2014 |
In vitro and in vivo assessment of dermatophyte acquired resistance to efinaconazole, a novel triazole antifungal.
Topics: Administration, Topical; Animals; Antifungal Agents; Colony Count, Microbial; Drug Resistance, Fungal; Guinea Pigs; Microbial Sensitivity Tests; Onychomycosis; Triazoles; Trichophyton | 2014 |
Nonclinical safety assessment of Efinaconazole Solution (10%) for onychomycosis treatment.
Topics: Administration, Cutaneous; Administration, Topical; Animals; Antifungal Agents; Dose-Response Relationship, Drug; Female; Injections, Subcutaneous; Male; Mice; Mice, Inbred ICR; No-Observed-Adverse-Effect Level; Onychomycosis; Pharmaceutical Solutions; Rats; Rats, Sprague-Dawley; Skin; Swine; Swine, Miniature; Time Factors; Triazoles | 2014 |
Efinaconazole topical solution (Jublia) for onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Drug Approval; Humans; Onychomycosis; Triazoles; United States; United States Food and Drug Administration | 2014 |
Proximal subungual onychomycosis caused by Fusarium falciforme successfully cured with posaconazole.
Topics: Antifungal Agents; Foot Dermatoses; Fusariosis; Fusarium; Humans; Male; Middle Aged; Molecular Sequence Data; Onychomycosis; Triazoles | 2015 |
Efinaconazole topical solution, 10%: formulation development program of a new topical treatment of toenail onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Chemistry, Pharmaceutical; Drug Delivery Systems; Foot Dermatoses; Humans; Nail Diseases; Nails; Onychomycosis; Permeability; Pharmaceutical Solutions; Solubility; Triazoles | 2015 |
Management of onychomycosis and co-existing tinea pedis.
Topics: Administration, Topical; Antifungal Agents; Clinical Trials as Topic; Humans; Onychomycosis; Severity of Illness Index; Tinea Pedis; Triazoles | 2015 |
Report of a case of a dermatophytoma successfully treated with topical efinaconazole 10% solution.
Topics: Administration, Topical; Aged; Antifungal Agents; Foot Dermatoses; Humans; Male; Naphthalenes; Onychomycosis; Terbinafine; Tinea; Treatment Outcome; Triazoles | 2015 |
Contact dermatitis caused by efinaconazole solution for treatment of onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Dermatitis, Allergic Contact; Humans; Male; Middle Aged; Onychomycosis; Patch Tests; Solutions; Triazoles | 2015 |
Molecular Identification of Candida Species Isolated from Onychomycosis in Shanghai, China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Candida; China; DNA, Fungal; DNA, Ribosomal Spacer; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Molecular Sequence Data; Onychomycosis; Prevalence; Sequence Analysis, DNA; Triazoles; Young Adult | 2015 |
Reevaluating the Need for Laboratory Testing in the Treatment of Onychomycosis: Safety and Cost-effectiveness Considerations.
Topics: Cost-Benefit Analysis; Health Care Costs; Humans; Naphthalenes; Onychomycosis; Triazoles | 2016 |
Evaluation of the Appearance of Nail Polish Following Daily Treatment of Ex Vivo Human Fingernails With Topical Solutions of Tavaborole or Efinaconazole.
Topics: Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Humans; Nails; Onychomycosis; Triazoles | 2016 |
How effective is efinaconazole in the management of onychomycosis?
Topics: Antifungal Agents; Disease Management; Humans; Nails; Onychomycosis; Pharmaceutical Solutions; Triazoles | 2016 |
Application of Hansen Solubility Parameters to predict drug-nail interactions, which can assist the design of nail medicines.
Topics: Adolescent; Adult; Antifungal Agents; Ciclopirox; Drug Interactions; Female; Humans; Keratins; Male; Middle Aged; Morpholines; Nail Diseases; Nails; Naphthalenes; Onychomycosis; Pharmaceutical Preparations; Pyridones; Solubility; Terbinafine; Triazoles; Young Adult | 2016 |
Onychomycosis: Strategies to Minimize Recurrence.
Topics: Administration, Topical; Antifungal Agents; Comorbidity; Diabetes Mellitus; Drug Administration Schedule; Humans; Itraconazole; Morpholines; Naphthalenes; Onychomycosis; Prevalence; Recurrence; Terbinafine; Tinea Pedis; Triazoles | 2016 |
Antifungal Drugs for Onychomycosis: Efficacy, Safety, and Mechanisms of Action.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Fluconazole; Foot Dermatoses; Humans; Itraconazole; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Treatment Outcome; Triazoles; United States | 2016 |
Introduction.
Topics: Administration, Cutaneous; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Foot Dermatoses; Humans; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Treatment Outcome; Triazoles | 2016 |
Using Topical Antifungal Medications: Instructions for patients.
Topics: Administration, Cutaneous; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Drug Administration Schedule; Foot Dermatoses; Humans; Onychomycosis; Pyridones; Triazoles | 2016 |
Response to "A financial perspective on the topical treatment of onychomycosis".
Topics: Administration, Topical; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cost-Benefit Analysis; Drug Costs; Female; Foot Dermatoses; Humans; Male; Onychomycosis; Sensitivity and Specificity; Severity of Illness Index; Triazoles | 2016 |
Ungual aspergillosis successfully treated with topical efinaconazole.
Topics: Administration, Topical; Aged; Antifungal Agents; Aspergillosis; Female; Humans; Onychomycosis; Triazoles | 2017 |
Tinea and Onychomycosis.
Topics: Administration, Cutaneous; Antifungal Agents; Humans; Imidazoles; Onychomycosis; Recurrence; Tinea; Tinea Pedis; Triazoles | 2016 |
Antimold Prophylaxis May Reduce the Risk of Invasive Fusariosis in Hematologic Patients with Superficial Skin Lesions with Positive Culture for Fusarium.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Antifungal Agents; Female; Fusariosis; Fusarium; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Intertrigo; Leukemia; Male; Middle Aged; Onychomycosis; Prospective Studies; Skin; Triazoles; Voriconazole; Young Adult | 2016 |
Update on Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Clinical Trials, Phase III as Topic; Humans; Onychomycosis; Solutions; Triazoles | 2016 |
Comparison of Characteristics of Two Topical Therapeutic Agents for Onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Dose-Response Relationship, Drug; Drug Discovery; Drug Resistance, Fungal; Humans; Imidazoles; In Vitro Techniques; Nails; Onychomycosis; Solutions; Triazoles; Trichophyton | 2016 |
Onychomadesis caused by efinaconazole.
Topics: Administration, Topical; Aged; Antifungal Agents; Dermatitis, Allergic Contact; Foot Dermatoses; Humans; Male; Nail Diseases; Onychomycosis; Patch Tests; Triazoles | 2017 |
Allergic contact dermatitis caused by efinaconazole: positive patch test reactions up to 0.1% pet.
Topics: Administration, Topical; Aged; Antifungal Agents; Dermatitis, Allergic Contact; Foot Dermatoses; Humans; Male; Onychomycosis; Patch Tests; Triazoles | 2017 |
Molecular identification and susceptibility testing of Trichosporon isolates from a Brazilian hospital.
Topics: Amphotericin B; Antifungal Agents; Brazil; Cross Infection; Dermatomycoses; Drug Resistance, Fungal; Echinocandins; Female; Flucytosine; Fungemia; Hospitals, University; Humans; Mycological Typing Techniques; Mycoses; Onychomycosis; Opportunistic Infections; Organ Specificity; Triazoles; Trichosporon; Urine; Vaginitis | 2008 |
In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis.
Topics: Analysis of Variance; Antifungal Agents; Arthrodermataceae; Candida; Colombia; Dose-Response Relationship, Drug; Fluconazole; Fungi; Fusarium; Humans; Itraconazole; Microbial Sensitivity Tests; Naphthalenes; Onychomycosis; Pyrimidines; Terbinafine; Triazoles; Voriconazole | 2010 |
Presumed Scopulariopsis brevicaulis chorioretinitis in a stem cell transplant recipient.
Topics: Adult; Antifungal Agents; Ascomycota; Chorioretinitis; Fluorescein Angiography; Humans; Macula Lutea; Male; Mitosporic Fungi; Onychomycosis; Stem Cell Transplantation; Triazoles | 2010 |
Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis.
Topics: Antifungal Agents; Aspergillus; Candida; Cryptococcus; Itraconazole; Microbial Sensitivity Tests; Morpholines; Naphthalenes; Onychomycosis; Pseudallescheria; Scopulariopsis; Terbinafine; Triazoles; Trichophyton; Trichosporon | 2013 |
Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine.
Topics: Administration, Oral; Administration, Topical; Animals; Antifungal Agents; Guinea Pigs; Male; Microbial Sensitivity Tests; Morpholines; Naphthalenes; Onychomycosis; Terbinafine; Tinea Pedis; Triazoles; Trichophyton | 2002 |
A case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin B.
Topics: Abscess; Amphotericin B; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cytarabine; Foot Dermatoses; Fusarium; Humans; Imatinib Mesylate; Immunocompromised Host; Liposomes; Male; Middle Aged; Muscular Diseases; Onychomycosis; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction; Reoperation; Rituximab; Teniposide; Triazoles; Voriconazole | 2006 |
[Therapy with voriconazol for a case of chronic mucocutaneous candidiasis].
Topics: Adult; Antifungal Agents; Candidiasis, Chronic Mucocutaneous; Drug Resistance, Multiple, Fungal; Female; Humans; Onychomycosis; Pyrimidines; Triazoles; Voriconazole | 2006 |
[Bilateral proximal cellulitis and onychomycosis in both big toes due to Fusarium solani].
Topics: Antifungal Agents; Cellulitis; Ciclopirox; Diabetes Mellitus, Type 2; Disease Susceptibility; Drug Resistance, Multiple, Fungal; Foot Dermatoses; Fusarium; Humans; Imidazoles; Immunocompetence; Itraconazole; Male; Middle Aged; Mozambique; Onychomycosis; Pyridones; Pyrimidines; Recurrence; Toes; Travel; Triazoles; Urea; Voriconazole | 2006 |
In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis.
Topics: Antifungal Agents; Arthrodermataceae; Drug Resistance, Multiple, Fungal; Fluconazole; Humans; Microbial Sensitivity Tests; Onychomycosis; Pyrimidines; Triazoles; Voriconazole | 2007 |
[In vitro susceptibility of isolates of Scytalidium spp. from superficial lesions against posaconazole].
Topics: Antifungal Agents; Ascomycota; Dermatomycoses; Drug Resistance, Fungal; Foot Dermatoses; Humans; Microbial Sensitivity Tests; Mitosporic Fungi; Onychomycosis; Triazoles | 2008 |
Disseminated dermatophytosis caused by Microsporum gypseum in two patients with the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antifungal Agents; Dermatomycoses; Female; Hand Dermatoses; Humans; Male; Microsporum; Onychomycosis; Piperazines; Skin; Triazoles | 1997 |